| Literature DB >> 32121011 |
Laura Esquius1,2, Ramon Segura1, Guillermo R Oviedo3, Marta Massip-Salcedo2, Casimiro Javierre1.
Abstract
Several studies have investigated the effects of fat intake before exercise on subsequent substrate oxidation and exercise performance. While some studies have reported that unsaturated fatty acid supplementation slightly increases fat oxidation, the changes have not been reflected in the maximum oxygen uptake or in other performance and physiological parameters. We selected almonds as a fatty acid (FA) source for acute supplementation and investigated their effect on non-esterified fatty acid (NEFA) values and exercise performance. Five physically active male subjects (age 32.9 ± 12.7 years, height 178.5 ± 3.3 cm, and weight 81.3 ± 9.7 kg) were randomly assigned to take an almond or placebo supplement 2 h before participating in two cycling resistance training sessions separated by an interval of 7-10 days. Their performance was evaluated with a maximal incremental test until exhaustion. Blood samples collected before, during, and after testing were biochemically analysed. The results indicated a NEFA value average increase of 0.09 mg·dL-1 (95% CI: 0.05-0.14; p < 0.001) after active supplement intake and enhanced performance (5389 ± 1795 W vs. placebo 4470 ± 2053 W, p = 0.043) after almond supplementation compared to the placebo. The almond supplementation did not cause gastrointestinal disturbances. Our study suggests that acute almond supplementation 2 h before exercise can improve performance in endurance exercise in trained subjects.Entities:
Keywords: almonds; ergogenic aids; exercise; non-esterified fatty acids; performance; sports nutrition; supplementation
Mesh:
Substances:
Year: 2020 PMID: 32121011 PMCID: PMC7146300 DOI: 10.3390/nu12030635
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Specific nutritional information for a “Marcona almond” (data from Survey (FNDDS), 2019) [20].
| Component | Amount | Unit |
|---|---|---|
| Water | 4.41 | g |
| Energy | 579 | kcal |
| Protein | 21.15 | g |
| Total lipid (fat) | 49.93 | g |
| Fatty acids, total saturated | 3.802 | g |
| 12:0 | 0 | g |
| 14:0 | 0.003 | g |
| 16:0 | 3.083 | g |
| 18:0 | 0.704 | g |
| Fatty acids, total monounsaturated | 31.551 | g |
| 16:1 | 0.239 | g |
| 18:1 | 31.294 | g |
| 20:1 | 0.005 | g |
| Fatty acids, total polyunsaturated | 12.329 | g |
| 18:2 | 12.324 | g |
| 18:3 | 0.003 | g |
| Carbohydrate, by difference | 21.55 | g |
| Fibre, total dietary | 12.5 | g |
| Sugars, total including NLEA | 4.35 | g |
Polyphenol composition of the almond (data from Bolling, 2017) [24].
| Polyphenol Class | Mean (range 25–75% percentile) (mg/100 g) |
|---|---|
| Proanthocyanidins (dimers and larger) | 162 (67.1–257) |
| Hydrolysable tannins | 82.1 (72.9–91.5) |
| Flavonoids, non-isoflavones | 61.2 (13.0–93.8) |
| Phenolic acids and aldehydes | 5.5 (5.16–12.2) |
| Minor phenolic constituents (isoflavones, stilbenes, lignans) | 0.7 (0.5–0.9) |
| Sum of classes | 312 (161–450) |
Ingredients and nutritional profile of the supplements.
| Active | Placebo | |
|---|---|---|
| Ingredients | 60 g almonds | 100 g white bread |
| 60 mL milk | 60 mL milk | |
| 6 g fructose | 6 g fructose | |
| Energy (kcal) | 405 | 315 |
| Fats (g) | 33.5 | 1.9 |
| Carbohydrates (g) | 12.5 | 63.2 |
| Proteins (g) | 13.5 | 11.2 |
Figure 1Protocol stages.
Submaximal test loadings.
| Subject | Power (W) | rpm |
|---|---|---|
| 1 | 75 | 60 |
| 2 | 125 | 60 |
| 3 | 125 | 60 |
| 4 | 125 | 70 |
| 5 | 125 | 70 |
Abbreviations: rpm = revolutions per minute.
Submaximal test metabolic results.
| Active | Placebo | ||||
|---|---|---|---|---|---|
| Variable | Mean | SD | Mean | SD |
|
| VO2 (L·min−1) | 2.27 | 0.25 | 2.24 | 0.41 | 0.085 |
| VCO2 (L·min−1) | 2.12 | 0.26 | 2.03 | 0.35 | 0.050 |
| RER | 0.93 | 0.00 | 0.91 | 0.06 | 0.000 |
| HR (bpm) | 123.00 | 16.42 | 120.52 | 12.15 | 0.010 |
Results are the mean ± standard deviation (SD). Abbreviations: VO2 = oxygen consumption; VCO2 = carbon dioxide production; RER = respiratory exchange ratio; HR = heart rate.
Maximal test performance.
| Active | Placebo | ||||||
|---|---|---|---|---|---|---|---|
| Subject | Time in Last Workload (min) | Maximum Power (W) | Total Work (W) | ΔTotal Work (W) | Time in Last Workload (min) | Maximum Power (W) | Total Work (W) |
| 1 | 3.6 | 200 | 4020 | 1995 | 4.5 | 150 | 2025 |
| 2 | 6 | 200 | 3150 | 663 | 4 | 200 | 2487 |
| 3 | 6 | 250 | 6000 | 500 | 4 | 250 | 5500 |
| 4 | 3.1 | 250 | 6134 | 214 | 2.5 | 250 | 5920 |
| 5 | 2 | 275 | 7642 | 1,225 | 4 | 250 | 6417 |
| Mean | 5389 | 919 | 4470 |
Maximal test metabolic results.
| Active | Placebo | ||||
|---|---|---|---|---|---|
| Variable | Mean | SD | Mean | SD |
|
| VO2 (L·min−1) | 3.38 | 0.59 | 3.44 | 0.52 | 0.814 |
| VCO2 (L·min−1) | 3.34 | 0.79 | 2.88 | 1.36 | 0.065 |
| RER | 1.00 | 0.07 | 0.97 | 0.08 | 0.005 |
| VE (L·min−1) | 100.80 | 36.3 | 89.3 | 31.50 | 0.000 |
| VT (L) | 2.64 | 0.48 | 2.90 | 0.61 | 0.063 |
| VO2kg (mL·kg·min−1) | 44.44 | 8.70 | 45.20 | 6.90 | 0.855 |
| HR (bpm) | 160.90 | 24.4 | 157.5 | 23.30 | 0.013 |
Results are the mean ± standard deviation (SD) in the last workload achieved for each subject. Abbreviations: VO2 = oxygen consumption; VCO2 = carbon dioxide production; RER = respiratory exchange ratio; VE = ventilation; VT = tidal volume; HR = heart rate.
Biochemical data after the submaximal test.
| Active | Placebo | ||||
|---|---|---|---|---|---|
| Variable | Mean | SD | Mean | SD |
|
| Lactate (m mol L−1) | 2.75 | 2.00 | 2.86 | 1.49 | 0.898 |
| TG (m mol L−1) | 127.48 | 46.86 | 111.19 | 29.79 | 0.016 |
| Cholesterol (mg·dL−1) | 177.29 | 51.72 | 182.71 | 40.72 | 0.822 |
| Glucose (mg·dL−1) | 89.09 | 17.97 | 89.04 | 16.27 | 0.995 |
| Uric acid (mg·dL−1) | 5.68 | 0.94 | 5.91 | 0.97 | 0.648 |
| Urea (mg·dL−1) | 41.02 | 5.79 | 40.71 | 6.32 | 0.921 |
| HDL (mg·dL−1) | 34.40 | 8.09 | 40.38 | 11.03 | 0.001 |
| GOT (UI·L−1) | 19.23 | 5.86 | 33.68 | 30.69 | 0.227 |
| GPT (UI·L−1) | 13.13 | 7.82 | 18.10 | 6.97 | 0.216 |
Results are the mean ± standard deviation (SD). Abbreviations: TG = triglycerides; HDL = high-density lipoprotein; GOT = glutamate-oxaloacetate-transaminase; GPT = glutamate-pyruvate transaminase.
Figure 2Evolution in NEFA plasma values after active and placebo supplementation. Results are the mean ± standard deviation (SD). A statistically significant increase in the mean values following active supplementation was found (0.09 mg· dL−1; p < 0.001). Abbreviations: NEFA = non-esterified fatty acids.